News & Events

Press Releases

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During “J.P. Morgan Week 2022”

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Events

Salarius Pharmaceuticals Oncology Pipeline Expansion Conference Call

Jan 13 @ 8:30 AM EST

Listen to Webcast

H.C. Wainwright BioConnect Conference

Jan 10

Biotech Showcase

Jan 10

Life Science Investor Forum

Dec 16

Listen to Webcast

In the News

The Clinical Trials Guru

David Arthur, Salarius CEO Speaks with Dan Sfera of The Clinical Trials Guru

Houston Business Journal

Salarius Pharmaceuticals raises millions for expanded clinical trial, moves office in TMC

15 Biotech Companies in Houston Making a Major Impact on Medicine

Empowered Patient Podcast

Targeting Epigenetic Causes of Ewing’s Sarcoma with David Arthur Salarius Pharmaceuticals on Empowered Patient Podcast with Karen Jagoda

Reportable News

Salarius During the JP Morgan Week – Attend the Biotech Showcase Presentation or Join the Live Webcast

Proactive Investors

Salarius Pharmaceuticals CEO talks through recent achievements for its lead cancer drug candidate